Comparative Effects of Single-Dose Cardioplegic Solutions Especially in Repeated Doses During Minimally Invasive Aortic Valve Surgery

Abstract

Objective

This study aims to compare del Nido cardioplegia (DNC) and histidine–tryptophan–ketoglutarate (HTK) cardioplegic solutions in minimally invasive aortic valve replacement (mini-AVR) surgery to discuss the safety level of myocardial protection and rationale for redosing intervals.

Methods

During the period from January 2017 to June 2019, 200 patients undergoing mini-AVR (solely or with concomitant procedures) were prospectively randomized to DNC (n = 100) and

HTK (n = 100), both up to 90 minutes ischemic time. Patients with ischemic time over 90 minutes, needing a redosing, were further analyzed in 2 subgroups with DNC-R (n = 30) and HTK-R (n = 36). Sensitive biomarkers, in addition to routine biochemistry, were also documented at baseline (T1), after cessation of cardiopulmonary bypass (T2), and on the first postoperative day (T3). Transmural myocardial biopsies were sampled for staining.

Results

No statistical differences could be demonstrated in DNC and HTK groups with up to 90 minutes cross-clamp times in routine biochemical measurements and basic perioperative clinical outcomes. DNC-R showed significantly more arrhythmia/AV block incidence resulting in more extended intensive care unit (ICU) stay. Interleukin-6 and syndecan-1 in DNC and DNC-R groups were substantially higher at T2. Aquaporin-4 levels were significantly lower in the DNC-R group, demonstrating unsatisfactory response of cells to an excessive volume at T2.

Conclusions

DNC and HTK provided acceptable myocardial protection as single-dose applications. DNC-R had significantly unbalanced levels of biomarkers, and more arrhythmia/AV block incidence resulting in more extended ICU stay. For patients who may need redosing HTK may be preferable to DNC.

Keywords

minimally invasive surgical procedures aortic valve heart arrest-induced Bretschneider cardioplegic solution

Get full access to this article

View all access options for this article.

References

Hoyer

Kiefer

Borger

. Cardioplegia and myocardial protection: time for a reassessment? J Thorac Dis 2019; 11: E76–E78.31285915

Stoliński

Plicner

Grudzień

et al. A comparison of minimally invasive and standard aortic valve replacement. J Thorac Cardiovasc Surg 2016; 152: 1030–1039.27449562

Ziazadeh

Mater

Himelhoch

et al. Single-dose del Nido cardioplegia in minimally invasive aortic valve surgery. Semin Thorac Cardiovasc Surg 2017; 29: 471–476.

Bretschneider

HJ.

Hübner

Knoll

et al. Myocardial resistance and tolerance to ischemia: physiological and biochemical basis. J Cardiovasc Surg 1975; 16: 241–260.239002

Hummel

BW.

Buss

RW.

DiGiorgi

et al. Myocardial protection and financial considerations of Custodiol cardioplegia in minimally invasive and open valve surgery. Innovations 2016; 11: 420–424.27879532

Matte

GS.

del Nido

. History and use of del Nido cardioplegia solution at Boston Children’s Hospital. J Extra Corpor Technol 2012; 44: 98–103.23198389

Talwar

Bhoje

Sreenivas

et al. Comparison of del Nido and St Thomas cardioplegia solutions in pediatric patients: a prospective randomized clinical trial. Semin Thorac Cardiovasc Surg 2017; 29: 366–374.29055711

Chen

Liu

et al. Which is the better option during neonatal cardiopulmonary bypass: HTK solution or cold blood cardioplegia? Asaio J 2013; 59: 69–74.23263337

Kalogeris

Baines

CP.

Krenz

et al. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol 2012; 298: 229–317.22878108

10.

Vistarini

Laliberté

Beauchamp

et al. Del Nido cardioplegia in the setting of minimally invasive aortic valve surgery. Perfusion 2017; 32: 112–117.27469246

11.

Luo

Shi

et al. Single-dose del Nido cardioplegia used in adult minimally invasive valve surgery. J Thorac Dis 2019; 11: 2373–2382.31372274

12.

Beyersdorf

Krause

Sarai

et al. Clinical evaluation of hypothermic ventricular fibrillation, multi-dose blood cardioplegia, and single-dose Bretschneider cardioplegia in coronary surgery. Thorac Cardiovasc Surg 1990; 38: 20–29.2106735

13.

Nicchia

GP.

Nico

Camassa

LMA

et al. The role of aquaporin-4 in the blood-brain barrier development and integrity: studies in animal and cell culture models. Neuroscience 2004; 129: 935–944.15561409

14.

Haywood-Watson

RJ.

Holcomb

JB.

Gonzalez

et al. Modulation of syndecan-1 shedding after hemorrhagic shock and resuscitation. PLoS One 2011; 6: e23530.21886795

15.

Koeckert

MS.

Smith

DE.

Vining

et al. Del Nido cardioplegia for minimally invasive aortic valve replacement. J Card Surg 2018; 33: 64–68.29460374

16.

Guajardo Salinas

GE.

Nutt

Rodriguez-Araujo

. Del Nido cardioplegia in low risk adults undergoing first time coronary artery bypass surgery. Perfusion 2017; 32: 68–73.27451052

17.

Gorgy

Shore-Lesserson

. Del Nido cardioplegia should be used in all adults undergoing cardiac surgery: con. J Cardiothorac Vasc Anesth 2019; 33: 1791–1794.30852089

18.

KR.

Rahman

IA.

Tam

et al. A systematic review and meta-analysis of del Nido versus conventional cardioplegia in adult cardiac surgery. Innovations 2019; 14: 385–393.31347414

19.

Durandy

. Is there a rationale for short cardioplegia re-dosing intervals? World J Cardiol 2015; 7: 658–664.26516420

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.19 MB

0.00 MB